What a mess this is, leadership with no real drug development experience. How many times has the R&D leader ever been to an FDA meeting, an EMA meeting, actually been involved in a submission of a regulatory filing? Zero? This post will be taken down because it is true and in R&D you have to tow the party line or your career will be distroyed. Amazing how someone threw MM and TZ under the bus when it suited them.
R&D leadership at MedImmune is a joke compared to other major biotech companies. They fly by the seat of their pants with little to no success in getting late stage Biologics approved and launched. Just a sad group of empty leaders with poor management skills.
Interesting. I am in Commercial so I can't really comment. Do you think Pascal will do some house cleaning?
My guess is that there is more housecleaning to come wherever AZ can reduce G&A costs. Anything that is done redundantly between MEDI and AZ will be seriously looked at. AZ really needs to cut costs with a slower growth rate now.
What is the status of th Medi-545 compound. This was the compound that senior Medi leaders wanted to push straight into phase 3 from phase 1. Wisely, a phase 2 study was undertaken before spending multiple millions of dollars on a phase 3 program in SLE. Rumors have it that the phase 2 is a bust, anyone hear anything?
The most recent P2 was the only successful P2 SLE trial to date. The ligand molecule is likely better, with results comingout in April/May. One is going to P3. MedI/AZ has a drug here.
How is MEDI1873 doing? It is in Ph1 too early, however, any input would be appreciated as I am a dying patient considering it.
